G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript
G1 Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.27. G1 Therapeutics, Inc.
G1 Therapeutics Inc. (GTHX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | D E Shaw D. E. Shaw | 495,451 | $1,511,126 | -2% | 0% |
| 2. | Marshall Wace LLP Paul Marshall And Ian Wace | 360,293 | $1,098,894 | -31% | 0% |
| 3. | Schonfeld Strategic Advisors Ryan Tolkin (Cio) | 340,784 | $1,039,391 | 0% | |
| 4. | Adage Capital Management Phill Gross And Robert Atchinson | 150,000 | $457,500 | 0% | |
| 5. | GLG Partners Noam Gottesman | 146,666 | $447,331 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.50 | 50,000 | 170,969 | 2020-11-18 | Filing | ||
| $12.83 | 4,000 | 8,000 | 2020-11-11 | Filing | ||
| $12.76 | 4,000 | 4,000 | 2020-11-10 | Filing | ||
| $14.95 | 1,000 | Officer | 4,000 | 2020-09-04 | Filing | |
| $18.25 | 1,000 | 3,000 | 2018-12-26 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.02 | 6,547 | 123,896 | 2024-03-18 | Filing | ||
| $4.62 | 28,600 | 169,938 | 2024-02-12 | Filing | ||
| $2.94 | 111 | 130,443 | 2024-01-04 | Filing | ||
| $3.12 | 379 | 130,554 | 2024-01-03 | Filing | ||
| $3.12 | 253 | 130,933 | 2024-01-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,981,673 | $6,044,102 | 0% | |
| 2. | 1,578,601 | $4,814,733 | 0% | |
| 3. | 680,664 | $2,076,026 | 0% | |
| 4. | 565,555 | $1,724,943 | 0% | |
| 5. | 521,327 | $1,590,047 | 0% |
News See All
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q3 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the G1 Therapeutics Third Quarter 2023 Financial Results Call. At this time, all participants are in a listen-only mode.
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q2 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the G1 Second Quarter Financial Results Conference Call. [Operator Instructions].
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q1 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the G1 Therapeutics First Quarter 2023 Financial Results Conference Call. Please be advised that today’s conference is being recorded.
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2022 Earnings Call Transcript
Operator: Good day and welcome to the G1 Therapeutics fourth quarter financial results conference call. At this time, all participants are in a listen-only mode.
5 Best Growth Stocks to Buy and Hold for Several Years
In this article we discuss the 5 best growth stocks to buy in 2021 and hold.
Were Hedge Funds Right About Betting On G1 Therapeutics, Inc. (GTHX)?
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC.
G1 Therapeutics, Inc. (GTHX): Are Hedge Funds Right About This Stock?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November.
Here is What Hedge Funds Think About G1 Therapeutics, Inc. (GTHX)
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge ...
Billionaire Hedge Funds
